Evaluation of antinuclear antibodies by indirect immunofluorescence and line immunoassay methods′: four years′ data from Turkey

Şener, Aslı Gamze; Afşar, İlhan; Demırcı, Mustafa

doi:10.1111/apm.12275

Cited by 17 publications

(13 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our study presents an ANA prevalence of 14.3% in non‐SARD patients, similar to that in general population reported previously , suggesting that various other diseases rather than SARDs cannot increase the risk of ANA production. Admittedly, since non‐SARDs were not specified in the current study, the conclusion must be explained in caution.…”

Section: Discussionsupporting

confidence: 90%

Prevalence of systemic autoimmune rheumatic diseases and clinical significance of ANA profile: data from a tertiary hospital in Shanghai, China

Yang

Ren

Liu

et al. 2016

APMIS

View full text Add to dashboard Cite

It is necessary and useful to explore prevalence of various systemic autoimmune rheumatic diseases (SARDs) in patients with suspicion of having SARDs and to characterize antinuclear antibodies (ANA) profile for identifying different populations (SARDs and non-SARDs). A total of 5024 consecutive patients with available medical records were investigated, whose sera had been tested for ANA profile, including ANA, anti-dsDNA and anti-extractable nuclear antigen (ENA) antibodies, between 31 January 2012 and 26 March 2014. Only 594 (11.8%) patients were diagnosed with SARDs of those suspected with SARDs. The prevalence of systemic lupus erythematosus (SLE) was highest (3.2%), followed by rheumatoid arthritis (RA) (2.5%), primary Sjögren's syndrome (pSS) (1.7%), ankylosing spondylitis (AS) (1.5%), etc. Of females, SLE also showed the highest prevalence (6%), while of males, AS showed the highest prevalence (1.9%). The prevalence of most SARDs was closely associated with age, except mixed connective tissue disease (MCTD), and the variation characteristics among different age groups were different among various SARDs. The prevalence of ANA was significantly increased in most SARD patients [especially in SLE, systemic sclerosis (SSc) and MCTD]. For anti-ENA antibodies, in contrast to some autoantibodies associated with multiple SARDs (e.g. anti-SSA, SSB, nRNP), others were relatively specific for certain diseases, such as anti-dsDNA, Sm, histone, nucleosome and Rib-P for SLE, anti-SCL-70 for SSc and anti-Jo-1 for polymyositis/dermatomyositis (PM/DM). Of note, ANA profile appeared to be of little significance for AS, ANCA-associated vasculitis (AAV), polymyalgia rheumatic (PMR), adult-onset Still's disease (ASD) and Behcet's disease (BD). The younger were more likely to have the presence of anti-dsDNA, Sm, histone or Rib-P for SLE, and anti-SSA for RA or MCTD. No significant differences for frequencies of ANA and anti-ENA autoantibodies were found between sexes in most SARDs, with the exception of RA and AS. The present study suggests that, of patients with SARDs-like clinical manifestations, the proportion of those with true SARDS is small, for most of whom tests for autoantibodies are necessary and useful to help make a prompt and precise diagnosis.

show abstract

Section: Discussionsupporting

confidence: 90%

Prevalence of systemic autoimmune rheumatic diseases and clinical significance of ANA profile: data from a tertiary hospital in Shanghai, China

Yang

Ren

Liu

et al. 2016

APMIS

View full text Add to dashboard Cite

show abstract

“…Only two other studies have been undertaken in India, in Bangalore by Sebastian et al 8 and in Chandigarh by Minz et al 6 Although the frequency of positivity in Bangalore was similar to the present study, Chandigarh showed a lesser positivity ( Table 6 ). Similar hospital-based studies done in Turkey by Zafer et al 9 and Sener et al 10 and in Belgium by Peene et al 7 had lesser positivity rate compared with present study. Although the results of these studies cannot be considered as prevalence, yet an estimation of disease burden can be made.…”

Section: Discussionsupporting

confidence: 89%

“…However, the present study and studies done by Chanwit et al and Sener et al found the rare ANA patterns in significant number, and also disease conditions associated with them, especially chronic hepatic conditions and carcinoma. 10 11 This supported the extensive study done by Pieter et al on rare ANA patterns, and his conclusion of nuclear envelope and nuclear dot patterns was associated with autoimmune hepatitis and hepatic and colon carcinoma. 17 The cytoplasmic patterns are also considered nondisease-specific but their significance should not be ignored, as stated by Chanwit et al, since they might as well point to certain undetected conditions.…”

Section: Discussionsupporting

confidence: 83%

A Hospital-Based Insight into the Antinuclear Antibody Patterns in Autoimmune Disorders

et al. 2020

View full text Add to dashboard Cite

Background The incidence of autoimmune disorders has seen a rise in India in recent times. The symptoms and signs of these conditions are caused by a systemic autoimmune response, essentially characterized by the expression of the antinuclear antibodies (ANA). Presence of ANA in serum of patient could be the prime evidence of an autoimmune disorder. Aim This study aimed to determine the antibody patterns and assess the clinical significance of ANA in patients of a teaching tertiary care hospital of central India. Material and Methods This retrospective cross-sectional data analysis study retrieved 538 reports of individuals, who were prescribed the ANA test by indirect immunofluorescence assay over a period of 11 months, from the archives of the Department of Biochemistry. For continuous data, student t-test was used while Chi-square and Fisher exact was conducted for categorical data. A p value less than 0.05 were taken as significant. Results Out of the 538 patients investigated for ANA testing by indirect immunofluorescence assay, 33% were positive, among which 74% were female, and majority belonged to the young adult age group. The most common pattern identified was nuclear, subpattern nuclear speckled. Conclusion A high-ANA pattern positivity could be related to a high-autoimmunity prevalence in this region, and also promotes its use as a tool of evidence of suspected autoimmune disorders.

show abstract

“…We found a higher rate of positive specific antibodies than previous study (35% vs. 16.9%). 14 Compared to previous studies that performed antigenspecific assay in all IIF-ANA negative sera and who found a rate of positivity of 0.7-14% [15][16][17] , we demonstrated that screening with EIA-ANA before performing antigenspecific assay in IIF-ANA negative sera may increase the probability of identifying specific antibodies.…”

Section: Discussionmentioning

confidence: 51%

Detection of Specific Autoantibodies in Sera with Negative Antinuclear Antibody by Indirect Immunofluorescence Assay but Positive by Enzyme Immunoassay

Viriyataveekul

Kobkitjaroen

2019

Siriraj Med Bull

View full text Add to dashboard Cite

The aim of this study was to investigate the predictive value of positive enzyme immunoassay (EIA) for detection of specific autoantibodies in sera negative for antinuclear antibody (ANA) by indirect immunofluorescence (IIF) assay, but positive for ANA by EIA. Methods: Eighty sera that tested negative for ANA by IIF, but positive for ANA by EIA were included. All sera were tested for specific autoantibodies by line immunoassay (LIA). The positive predictive value (PPV) of EIA was calculated using LIA result as a reference standard. Medical records of patients were reviewed. Clinical findings at the time of blood sampling for ANA testing and at 5 years after sampling were obtained. Results: Twenty-eight sera (35%) were found to be positive by LIA. The PPV of EIA for detection of specific autoantibodies at the manufacturer's recommended cutoff was 35.0% (95% CI: 24.5-45.5%). The most prevalent antibodies were anti-SSA/Ro60 (64.3%, 95% CI: 46.5-82.0%), anti-Ro52 (25.0%, 95% CI: 9.0-41.0%), and anti-SSB/ La (10.7%, 95% CI: 0-22.2%). A diagnosis of systemic autoimmune rheumatic disease was established in 7 patients (25%) at the time of blood sampling, and 4 patients (14.3%) were diagnosed with non-rheumatic autoimmune disease. Conclusion: EIA testing in IIF-ANA negative sera yielded a chance to detect antinuclear antibodies. However, the poor PPV of EIA may have low benefit in real-life clinical practice. Anti-SSA/Ro60 was the most prevalent antibody detected. A high proportion of LIA-ANA positive patients were not diagnosed as autoimmune disease at the time of antibody detection.

show abstract

Evaluation of antinuclear antibodies by indirect immunofluorescence and line immunoassay methods′: four years′ data from Turkey

Cited by 17 publications

References 18 publications

Prevalence of systemic autoimmune rheumatic diseases and clinical significance of ANA profile: data from a tertiary hospital in Shanghai, China

Prevalence of systemic autoimmune rheumatic diseases and clinical significance of ANA profile: data from a tertiary hospital in Shanghai, China

A Hospital-Based Insight into the Antinuclear Antibody Patterns in Autoimmune Disorders

Detection of Specific Autoantibodies in Sera with Negative Antinuclear Antibody by Indirect Immunofluorescence Assay but Positive by Enzyme Immunoassay

Contact Info

Product

Resources

About